Kamura T, Koepp DM, Conrad MN, Skowyra D, Moreland RJ, Iliopoulos O, Lane WS, Kaelin WG, Elledge SJ, Conaway RC, Harper JW, Conaway JW
Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase. Science. 1999 Apr 23; 284(5414):657-61.
Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase.
Clinical cancer research : an official journal of the American Association for Cancer Research
Molecular markers for early detection of renal carcinoma: investigative approach. Clin Cancer Res. 2004 Sep 15; 10(18 Pt 2):6296S-301S.
Molecular markers for early detection of renal carcinoma: investigative approach.
Iliopoulos O, Kibel A, Gray S, Kaelin WG
Tumour suppression by the human von Hippel-Lindau gene product. Nat Med. 1995 Aug; 1(8):822-6.
Tumour suppression by the human von Hippel-Lindau gene product.
Metallo CM, Gameiro PA, Bell EL, Mattaini KR, Yang J, Hiller K, Jewell CM, Johnson ZR, Irvine DJ, Guarente L, Kelleher JK, Vander Heiden MG, Iliopoulos O, Stephanopoulos G
Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature. 2011 Nov 20; 481(7381):380-4.
Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia.
Scherber C, Aranyosi AJ, Kulemann B, Thayer SP, Toner M, Iliopoulos O, Irimia D
Integrative biology : quantitative biosciences from nano to macro
Epithelial cell guidance by self-generated EGF gradients. Integr Biol (Camb). 2012 Mar; 4(3):259-69.
Epithelial cell guidance by self-generated EGF gradients.
Tousi F, Bones J, Iliopoulos O, Hancock WS, Hincapie M
Multidimensional liquid chromatography platform for profiling alterations of clusterin N-glycosylation in the plasma of patients with renal cell carcinoma. J Chromatogr A. 2012 Sep 21; 1256:121-8.
Multidimensional liquid chromatography platform for profiling alterations of clusterin N-glycosylation in the plasma of patients with renal cell carcinoma.
Dahl DM, Simeone JF, Iliopoulos O, Saylor PJ, Wu CL
Case 36-2018: A 29-Year-Old Man with an Incidentally Discovered Renal Mass. N Engl J Med. 2018 11 22; 379(21):2064-2072.
Case 36-2018: A 29-Year-Old Man with an Incidentally Discovered Renal Mass.
Genetic and clinical aspects of familial renal neoplasms. Semin Oncol. 2000 Apr; 27(2):138-49.
Genetic and clinical aspects of familial renal neoplasms.
Molecular genetics of kidney cancer. Cancer Treat Res. 2003; 116:3-27.
Atkins MB, Avigan DE, Bukowski RM, Childs RW, Dutcher JP, Eisen TG, Figlin RA, Finke JH, Flanigan RC, George DJ, Goldberg SN, Gordon MS, Iliopoulos O, Kaelin WG, Linehan WM, Lipton A, Motzer RJ, Novick AC, Stadler WM, Teh BT, Yang JC, King L
Innovations and challenges in renal cancer: consensus statement from the first international conference. Clin Cancer Res. 2004 Sep 15; 10(18 Pt 2):6277S-81S.
Innovations and challenges in renal cancer: consensus statement from the first international conference.
Gameiro PA, Yang J, Metelo AM, Pérez-Carro R, Baker R, Wang Z, Arreola A, Rathmell WK, Olumi A, López-Larrubia P, Stephanopoulos G, Iliopoulos O
In vivo HIF-mediated reductive carboxylation is regulated by citrate levels and sensitizes VHL-deficient cells to glutamine deprivation. Cell Metab. 2013 Mar 05; 17(3):372-85.
In vivo HIF-mediated reductive carboxylation is regulated by citrate levels and sensitizes VHL-deficient cells to glutamine deprivation.
Naclerio RM, Kagey-Sobotka A, Lichtenstein LM, Togias AG, Iliopoulos O, Pipkorn U, Bascom R, Norman PS, Proud D
Observations on nasal late phase reactions. Immunol Invest. 1987-1988 Dec; 16(8):649-85.
Observations on nasal late phase reactions.
Von Hippel-Lindau Tumor Suppressor Protein
Jerome and Nancy Kohlberg Professor of Medicine
Edward Wigglesworth Professor of Dermatology
Walter S. Kerr, Jr. Distinguished Professor of Surgery
Madala HR, Helenius IT, Zhou W, Mills E, Zhang Y, Liu Y, Metelo AM, Kelley ML, Punganuru S, Kim KB, Olenchock B, Rhee E, Intlekofer AM, Iliopoulos O, Chouchani E, Yeh JJ
Nitrogen Trapping as a Therapeutic Strategy in Tumors with Mitochondrial Dysfunction. Cancer Res. 2020 09 01; 80(17):3492-3506.
Nitrogen Trapping as a Therapeutic Strategy in Tumors with Mitochondrial Dysfunction.
Chahoud J, McGettigan M, Parikh N, Boris RS, Iliopoulos O, Rathmell WK, Daniels AB, Jonasch E, Spiess PE
Evaluation, diagnosis and surveillance of renal masses in the setting of VHL disease. World J Urol. 2021 Jul; 39(7):2409-2415.
Evaluation, diagnosis and surveillance of renal masses in the setting of VHL disease.
Keibler MA, Dong W, Korthauer KD, Hosios AM, Moon SJ, Sullivan LB, Liu N, Abbott KL, Arevalo OD, Ho K, Lee J, Phanse AS, Kelleher JK, Iliopoulos O, Coloff JL, Vander Heiden MG, Stephanopoulos G
Differential substrate use in EGF- and oncogenic KRAS-stimulated human mammary epithelial cells. FEBS J. 2021 10; 288(19):5629-5649.
Differential substrate use in EGF- and oncogenic KRAS-stimulated human mammary epithelial cells.
Allouche J, Rachmin I, Adhikari K, Pardo LM, Lee JH, McConnell AM, Kato S, Fan S, Kawakami A, Suita Y, Wakamatsu K, Igras V, Zhang J, Navarro PP, Lugo CM, Noonan HR, Christie KA, Itin K, Mujahid N, Lo JA, Won CH, Evans CL, Weng QY, Wang H, Osseiran S, Lovas A, Németh I, Cozzio A, Navarini AA, Hsiao JJ, Nguyen N, Kemény LV, Iliopoulos O, Berking C, Ruzicka T, Gonzalez-José R, Bortolini MC, Canizales-Quinteros S, Acuna-Alonso V, Gallo C, Poletti G, Bedoya G, Rothhammer F, Ito S, Schiaffino MV, Chao LH, Kleinstiver BP, Tishkoff S, Zon LI, Nijsten T, Ruiz-Linares A, Fisher DE, Roider E
NNT mediates redox-dependent pigmentation via a UVB- and MITF-independent mechanism. Cell. 2021 08 05; 184(16):4268-4283.e20.
NNT mediates redox-dependent pigmentation via a UVB- and MITF-independent mechanism.
Bratslavsky G, Mendhiratta N, Daneshvar M, Brugarolas J, Ball MW, Metwalli A, Nathanson KL, Pierorazio PM, Boris RS, Singer EA, Carlo MI, Daly MB, Henske EP, Hyatt C, Middleton L, Morris G, Jeong A, Narayan V, Rathmell WK, Vaishampayan U, Lee BH, Battle D, Hall MJ, Hafez K, Jewett MAS, Karamboulas C, Pal SK, Hakimi AA, Kutikov A, Iliopoulos O, Linehan WM, Jonasch E, Srinivasan R, Shuch B
Genetic risk assessment for hereditary renal cell carcinoma: Clinical consensus statement. Cancer. 2021 Nov 01; 127(21):3957-3966.
Genetic risk assessment for hereditary renal cell carcinoma: Clinical consensus statement.
Calvo IA, Sharma S, Paulo JA, Gulka AOD, Boeszoermenyi A, Zhang J, Lombana JM, Palmieri CM, Laviolette LA, Arthanari H, Iliopoulos O, Gygi SP, Motamedi M
The fission yeast FLCN/FNIP complex augments TORC1 repression or activation in response to amino acid (AA) availability. iScience. 2021 Nov 19; 24(11):103338.
The fission yeast FLCN/FNIP complex augments TORC1 repression or activation in response to amino acid (AA) availability.
Jonasch E, Donskov F, Iliopoulos O, Rathmell WK, Narayan VK, Maughan BL, Oudard S, Else T, Maranchie JK, Welsh SJ, Thamake S, Park EK, Perini RF, Linehan WM, Srinivasan R
Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease. N Engl J Med. 2021 11 25; 385(22):2036-2046.
Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease.
Woodford MR, Andreou A, Baba M, van de Beek I, Di Malta C, Glykofridis I, Grimes H, Henske EP, Iliopoulos O, Kurihara M, Lazor R, Linehan WM, Matsumoto K, Marciniak SJ, Namba Y, Pause A, Rajan N, Ray A, Schmidt LS, Shi W, Steinlein OK, Thierauf J, Zoncu R, Webb A, Mollapour M
Seventh BHD international symposium: recent scientific and clinical advancement. Oncotarget. 2022; 13:173-181.
Seventh BHD international symposium: recent scientific and clinical advancement.
Meric-Bernstam F, Tannir NM, Iliopoulos O, Lee RJ, Telli ML, Fan AC, DeMichele A, Haas NB, Patel MR, Harding JJ, Voss MH, Owonikoko TK, Carthon B, Srinivasan R, Bendell JC, Jenkins Y, Whiting SH, Orford K, Bennett MK, Bauer TM
Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial. Clin Cancer Res. 2022 04 14; 28(8):1540-1548.
Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial.
Arevalo A, Patel N, Muraki P, Ohtake S, Bratslavsky G, Clark C, Mann J, Iliopoulos O, Jonasch E, Srinivasan R, Shuch B
Understanding the Impact of Belzutifan on Treatment Strategies for Patients with VHL. J Kidney Cancer VHL. 2022; 9(3):41-46.
Understanding the Impact of Belzutifan on Treatment Strategies for Patients with VHL.
Diseases of Hereditary Renal Cell Cancers. Urol Clin North Am. 2023 May; 50(2):205-215.
Diseases of Hereditary Renal Cell Cancers.
Roider E, Lakatos AIT, McConnell AM, Wang P, Mueller A, Kawakami A, Tsoi J, Szabolcs BL, Ascsillán AA, Suita Y, Igras V, Lo JA, Hsiao JJ, Lapides R, Pál DMP, Lengyel AS, Navarini A, Okazaki A, Iliopoulos O, Németh I, Graeber TG, Zon L, Giese RW, Kemeny LV, Fisher DE
bioRxiv : the preprint server for biology
MITF regulates IDH1 and NNT and drives a transcriptional program protecting cutaneous melanoma from reactive oxygen species. bioRxiv. 2023 Nov 14.
MITF regulates IDH1 and NNT and drives a transcriptional program protecting cutaneous melanoma from reactive oxygen species.
Else T, Jonasch E, Iliopoulos O, Beckermann KE, Narayan V, Maughan BL, Oudard S, Maranchie JK, Iversen AB, Goldberg CM, Fu W, Perini RF, Liu Y, Linehan WM, Srinivasan R
Belzutifan for von Hippel-Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study. Clin Cancer Res. 2024 May 01; 30(9):1750-1757.
Belzutifan for von Hippel-Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study.
Gameiro PA, Laviolette LA, Kelleher JK, Iliopoulos O, Stephanopoulos G
Cofactor balance by nicotinamide nucleotide transhydrogenase (NNT) coordinates reductive carboxylation and glucose catabolism in the tricarboxylic acid (TCA) cycle. J Biol Chem. 2013 May 03; 288(18):12967-77.
Cofactor balance by nicotinamide nucleotide transhydrogenase (NNT) coordinates reductive carboxylation and glucose catabolism in the tricarboxylic acid (TCA) cycle.
Laviolette LA, Wilson J, Koller J, Neil C, Hulick P, Rejtar T, Karger B, Teh BT, Iliopoulos O
Human folliculin delays cell cycle progression through late S and G2/M-phases: effect of phosphorylation and tumor associated mutations. PLoS One. 2013; 8(7):e66775.
Human folliculin delays cell cycle progression through late S and G2/M-phases: effect of phosphorylation and tumor associated mutations.
Iliopoulos O, Iversen AB, Narayan V, Maughan BL, Beckermann KE, Oudard S, Else T, Maranchie JK, Goldberg CM, Fu W, Perini RF, Liu Y, Linehan WM, Srinivasan R, Jonasch E
Belzutifan for patients with von Hippel-Lindau disease-associated CNS haemangioblastomas (LITESPARK-004): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2024 10; 25(10):1325-1336.
Belzutifan for patients with von Hippel-Lindau disease-associated CNS haemangioblastomas (LITESPARK-004): a multicentre, single-arm, phase 2 study.
MITF regulates IDH1, NNT, and a transcriptional program protecting melanoma from reactive oxygen species. Sci Rep. 2024 09 14; 14(1):21527.
MITF regulates IDH1, NNT, and a transcriptional program protecting melanoma from reactive oxygen species.
Rafalko A, Iliopoulos O, Fusaro VA, Hancock W, Hincapie M
Immunoaffinity enrichment and liquid chromatography-selected reaction monitoring mass spectrometry for quantitation of carbonic anhydrase 12 in cultured renal carcinoma cells. Anal Chem. 2010 Nov 01; 82(21):8998-9005.
Immunoaffinity enrichment and liquid chromatography-selected reaction monitoring mass spectrometry for quantitation of carbonic anhydrase 12 in cultured renal carcinoma cells.
Trinh MN, Bear L, Nahed BV, Iliopoulos O
"Incidentally" discovered Von Hippel Lindau disease: an emerging clinical phenotype. Oncologist. 2025 Mar 10; 30(3).
"Incidentally" discovered Von Hippel Lindau disease: an emerging clinical phenotype.
Srinivasan R, Iliopoulos O, Beckermann KE, Narayan V, Maughan BL, Oudard S, Else T, Maranchie JK, Iversen AB, Cornell J, Perini RF, Liu Y, Linehan WM, Jonasch E
Belzutifan for von Hippel-Lindau disease-associated renal cell carcinoma and other neoplasms (LITESPARK-004): 50 months follow-up from a single-arm, phase 2 study. Lancet Oncol. 2025 May; 26(5):571-582.
Belzutifan for von Hippel-Lindau disease-associated renal cell carcinoma and other neoplasms (LITESPARK-004): 50 months follow-up from a single-arm, phase 2 study.
Sundaram M, Atkinson C, Cooper C, Taylor-Stokes G, Mann J, Iliopoulos O
The impact of surgery on patients with Von Hippel-Lindau-associated tumors: an international patient survey. Oncologist. 2025 Sep 01; 30(9).
The impact of surgery on patients with Von Hippel-Lindau-associated tumors: an international patient survey.
Jimenez C, Andreassen M, Durand A, Moog S, Hendifar A, Welin S, Spada F, Sharma R, Wolin E, Ruether J, Garcia-Carbonero R, Fassnacht M, Capdevila J, Del Rivero J, Iliopoulos O, Huillard O, Jang R, Mai K, Artamonova E, Hallqvist A, Else T, Odeleye-Ajakaye A, Gozman A, Naik GS, Berruti A
Belzutifan for Advanced Pheochromocytoma or Paraganglioma. N Engl J Med. 2025 Nov 20; 393(20):2012-2022.
Belzutifan for Advanced Pheochromocytoma or Paraganglioma.
Gbormittah FO, Lee LY, Taylor K, Hancock WS, Iliopoulos O
Comparative studies of the proteome, glycoproteome, and N-glycome of clear cell renal cell carcinoma plasma before and after curative nephrectomy. J Proteome Res. 2014 Nov 07; 13(11):4889-900.
Comparative studies of the proteome, glycoproteome, and N-glycome of clear cell renal cell carcinoma plasma before and after curative nephrectomy.
Gbormittah FO, Bones J, Hincapie M, Tousi F, Hancock WS, Iliopoulos O
Clusterin glycopeptide variant characterization reveals significant site-specific glycan changes in the plasma of clear cell renal cell carcinoma. J Proteome Res. 2015 Jun 05; 14(6):2425-36.
Clusterin glycopeptide variant characterization reveals significant site-specific glycan changes in the plasma of clear cell renal cell carcinoma.
Metelo AM, Noonan HR, Li X, Jin Y, Baker R, Kamentsky L, Zhang Y, van Rooijen E, Shin J, Carpenter AE, Yeh JR, Peterson RT, Iliopoulos O
Pharmacological HIF2a inhibition improves VHL disease-associated phenotypes in zebrafish model. J Clin Invest. 2015 May; 125(5):1987-97.
Pharmacological HIF2a inhibition improves VHL disease-associated phenotypes in zebrafish model.
Black JC, Atabakhsh E, Kim J, Biette KM, Van Rechem C, Ladd B, Burrowes PD, Donado C, Mattoo H, Kleinstiver BP, Song B, Andriani G, Joung JK, Iliopoulos O, Montagna C, Pillai S, Getz G, Whetstine JR
Hypoxia drives transient site-specific copy gain and drug-resistant gene expression. Genes Dev. 2015 May 15; 29(10):1018-31.
Hypoxia drives transient site-specific copy gain and drug-resistant gene expression.
HIF2a inhibitors for the treatment of VHL disease. Oncotarget. 2015 Sep 15; 6(27):23036-7.
HIF2a inhibitors for the treatment of VHL disease.
Noonan HR, Metelo AM, Kamei CN, Peterson RT, Drummond IA, Iliopoulos O
Loss of vhl in the zebrafish pronephros recapitulates early stages of human clear cell renal cell carcinoma. Dis Model Mech. 2016 08 01; 9(8):873-84.
Loss of vhl in the zebrafish pronephros recapitulates early stages of human clear cell renal cell carcinoma.
Keibler MA, Wasylenko TM, Kelleher JK, Iliopoulos O, Vander Heiden MG, Stephanopoulos G
Metabolic requirements for cancer cell proliferation. Cancer Metab. 2016; 4:16.
Metabolic requirements for cancer cell proliferation.
Hypoxia-induced Metabolic Changes in Cancer
TUMOR SUPPRESSOR PVHL FUNCTIONAL INTERACTION WITH CUL2
Identification of Biomarkers for Early Detection of Renal Cell Carcinoma
Molecular targets of hypoxia in signaling cancer
Assessment of Overall Survival, Quality of Life, and Safety Benefits Associated With New Cancer Medicines. JAMA Oncol. 2017 Mar 01; 3(3):382-390.
Assessment of Overall Survival, Quality of Life, and Safety Benefits Associated With New Cancer Medicines.
Iliopoulos O, Levy AP, Jiang C, Kaelin WG, Goldberg MA
Proceedings of the National Academy of Sciences of the United States of America
Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci U S A. 1996 Oct 01; 93(20):10595-9.
Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein.
Lonergan KM, Iliopoulos O, Ohh M, Kamura T, Conaway RC, Conaway JW, Kaelin WG
Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cul2. Mol Cell Biol. 1998 Feb; 18(2):732-41.
Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cul2.
Wen SF, Parthasarathy R, Iliopoulos O, Oberley TD
American journal of kidney diseases : the official journal of the National Kidney Foundation
Acute renal failure following binge drinking and nonsteroidal antiinflammatory drugs. Am J Kidney Dis. 1992 Sep; 20(3):281-5.
Acute renal failure following binge drinking and nonsteroidal antiinflammatory drugs.
Levy AP, Levy NS, Iliopoulos O, Jiang C, Kaplin WG, Goldberg MA
Regulation of vascular endothelial growth factor by hypoxia and its modulation by the von Hippel-Lindau tumor suppressor gene. Kidney Int. 1997 Feb; 51(2):575-8.
Regulation of vascular endothelial growth factor by hypoxia and its modulation by the von Hippel-Lindau tumor suppressor gene.
Iliopoulos O, Proud D, Norman PS, Lichtenstein LM, Kagey-Sobotka A, Naclerio RM
The American review of respiratory disease
Nasal challenge with cold, dry air induces a late-phase reaction. Am Rev Respir Dis. 1988 Aug; 138(2):400-5.
Nasal challenge with cold, dry air induces a late-phase reaction.
Okazaki A, Gameiro PA, Christodoulou D, Laviollette L, Schneider M, Chaves F, Stemmer-Rachamimov A, Yazinski SA, Lee R, Stephanopoulos G, Zou L, Iliopoulos O
Glutaminase and poly(ADP-ribose) polymerase inhibitors suppress pyrimidine synthesis and VHL-deficient renal cancers. J Clin Invest. 2017 May 01; 127(5):1631-1645.
Glutaminase and poly(ADP-ribose) polymerase inhibitors suppress pyrimidine synthesis and VHL-deficient renal cancers.
Iliopoulos O, Chan-Smutko G, Gonzalez RG, Louis DN, Stone JR
Case records of the Massachusetts General Hospital. Case 23-2006. A 36-year-old man with numbness in the left [corrected] hand and hypertension. N Engl J Med. 2006 Jul 27; 355(4):394-402.
Case records of the Massachusetts General Hospital. Case 23-2006. A 36-year-old man with numbness in the left [corrected] hand and hypertension.
pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation. Proc Natl Acad Sci U S A. 1998 Sep 29; 95(20):11661-6.
pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation.
von Hippel-Lindau disease: genetic and clinical observations. Front Horm Res. 2001; 28:131-66.
von Hippel-Lindau disease: genetic and clinical observations.
Kaelin WG, Iliopoulos O, Lonergan KM, Ohh M
Functions of the von Hippel-Lindau tumour suppressor protein. J Intern Med. 1998 Jun; 243(6):535-9.
Functions of the von Hippel-Lindau tumour suppressor protein.
Mizukami Y, Li J, Zhang X, Zimmer MA, Iliopoulos O, Chung DC
Hypoxia-inducible factor-1-independent regulation of vascular endothelial growth factor by hypoxia in colon cancer. Cancer Res. 2004 Mar 01; 64(5):1765-72.
Hypoxia-inducible factor-1-independent regulation of vascular endothelial growth factor by hypoxia in colon cancer.
Iliopoulos O, Proud D, Adkinson NF, Creticos PS, Norman PS, Kagey-Sobotka A, Lichtenstein LM, Naclerio RM
The Journal of allergy and clinical immunology
Effects of immunotherapy on the early, late, and rechallenge nasal reaction to provocation with allergen: changes in inflammatory mediators and cells. J Allergy Clin Immunol. 1991 Apr; 87(4):855-66.
Effects of immunotherapy on the early, late, and rechallenge nasal reaction to provocation with allergen: changes in inflammatory mediators and cells.
Ohh M, Yauch RL, Lonergan KM, Whaley JM, Stemmer-Rachamimov AO, Louis DN, Gavin BJ, Kley N, Kaelin WG, Iliopoulos O
The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol Cell. 1998 Jun; 1(7):959-68.
The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix.
Zimmer M, Ebert BL, Neil C, Brenner K, Papaioannou I, Melas A, Tolliday N, Lamb J, Pantopoulos K, Golub T, Iliopoulos O
Small-molecule inhibitors of HIF-2a translation link its 5'UTR iron-responsive element to oxygen sensing. Mol Cell. 2008 Dec 26; 32(6):838-48.
Small-molecule inhibitors of HIF-2a translation link its 5'UTR iron-responsive element to oxygen sensing.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Molecular biology of renal cell cancer and the identification of therapeutic targets. J Clin Oncol. 2006 Dec 10; 24(35):5593-600.
Molecular biology of renal cell cancer and the identification of therapeutic targets.
Schneider M, Dinkelborg K, Xiao X, Chan-Smutko G, Hruska K, Huang D, Sagar P, Harisinghani M, Iliopoulos O
Early onset renal cell carcinoma in an adolescent girl with germline FLCN exon 5 deletion. Fam Cancer. 2018 01; 17(1):135-139.
Early onset renal cell carcinoma in an adolescent girl with germline FLCN exon 5 deletion.
Laviolette LA, Mermoud J, Calvo IA, Olson N, Boukhali M, Steinlein OK, Roider E, Sattler EC, Huang D, Teh BT, Motamedi M, Haas W, Iliopoulos O
Negative regulation of EGFR signalling by the human folliculin tumour suppressor protein. Nat Commun. 2017 06 28; 8:15866.
Negative regulation of EGFR signalling by the human folliculin tumour suppressor protein.
Kibel A, Iliopoulos O, DeCaprio JA, Kaelin WG
Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C. Science. 1995 Sep 08; 269(5229):1444-6.
Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C.
Charlesworth EN, Iliopoulos O, MacDonald SM, Kagey-Sobotka A, Lichtenstein LM
International archives of allergy and applied immunology
Cells and secretagogues involved in the human late-phase response. Int Arch Allergy Appl Immunol. 1989; 88(1-2):50-3.
Cells and secretagogues involved in the human late-phase response.
Heddleston JM, Wu Q, Rivera M, Minhas S, Lathia JD, Sloan AE, Iliopoulos O, Hjelmeland AB, Rich JN
Hypoxia-induced mixed-lineage leukemia 1 regulates glioma stem cell tumorigenic potential. Cell Death Differ. 2012 Mar; 19(3):428-39.
Hypoxia-induced mixed-lineage leukemia 1 regulates glioma stem cell tumorigenic potential.
Chemical Biology of IRP1-HIF2a Signaling
The molecular basis of von Hippel-Lindau disease. Mol Med. 1997 May; 3(5):289-93.
The molecular basis of von Hippel-Lindau disease.
Zimmer M, Doucette D, Siddiqui N, Iliopoulos O
Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/- tumors. Mol Cancer Res. 2004 Feb; 2(2):89-95.
Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/- tumors.
Mizukami Y, Jo WS, Duerr EM, Gala M, Li J, Zhang X, Zimmer MA, Iliopoulos O, Zukerberg LR, Kohgo Y, Lynch MP, Rueda BR, Chung DC
Induction of interleukin-8 preserves the angiogenic response in HIF-1alpha-deficient colon cancer cells. Nat Med. 2005 Sep; 11(9):992-7.
Induction of interleukin-8 preserves the angiogenic response in HIF-1alpha-deficient colon cancer cells.
Michaelson MD, Iliopoulos O, McDermott DF, McGovern FJ, Harisinghani MG, Oliva E
Case records of the Massachusetts General Hospital. Case 17-2008. A 63-year-old man with metastatic renal-cell carcinoma. N Engl J Med. 2008 May 29; 358(22):2389-96.
Case records of the Massachusetts General Hospital. Case 17-2008. A 63-year-old man with metastatic renal-cell carcinoma.
Nicolay BN, Gameiro PA, Tschöp K, Korenjak M, Heilmann AM, Asara JM, Stephanopoulos G, Iliopoulos O, Dyson NJ
Loss of RBF1 changes glutamine catabolism. Genes Dev. 2013 Jan 15; 27(2):182-96.
Loss of RBF1 changes glutamine catabolism.
Zhong L, D'Urso A, Toiber D, Sebastian C, Henry RE, Vadysirisack DD, Guimaraes A, Marinelli B, Wikstrom JD, Nir T, Clish CB, Vaitheesvaran B, Iliopoulos O, Kurland I, Dor Y, Weissleder R, Shirihai OS, Ellisen LW, Espinosa JM, Mostoslavsky R
The histone deacetylase Sirt6 regulates glucose homeostasis via Hif1alpha. Cell. 2010 Jan 22; 140(2):280-93.
The histone deacetylase Sirt6 regulates glucose homeostasis via Hif1alpha.
Togias A, Naclerio RM, Proud D, Pipkorn U, Bascom R, Iliopoulos O, Kagey-Sobotka A, Norman PS, Lichtenstein LM
Studies on the allergic and nonallergic nasal inflammation. J Allergy Clin Immunol. 1988 May; 81(5 Pt 1):782-90.
Studies on the allergic and nonallergic nasal inflammation.
Iliopoulos O, Proud D, Adkinson NF, Norman PS, Kagey-Sobotka A, Lichtenstein LM, Naclerio RM
Relationship between the early, late, and rechallenge reaction to nasal challenge with antigen: observations on the role of inflammatory mediators and cells. J Allergy Clin Immunol. 1990 Dec; 86(6 Pt 1):851-61.
Relationship between the early, late, and rechallenge reaction to nasal challenge with antigen: observations on the role of inflammatory mediators and cells.
Bhatt RS, Landis DM, Zimmer M, Torregrossa J, Chen S, Sukhatme VP, Iliopoulos O, Balk S, Bubley GJ
Hypoxia-inducible factor-2alpha: effect on radiation sensitivity and differential regulation by an mTOR inhibitor. BJU Int. 2008 Aug; 102(3):358-63.
Hypoxia-inducible factor-2alpha: effect on radiation sensitivity and differential regulation by an mTOR inhibitor.
Zimmer M, Lamb J, Ebert BL, Lynch M, Neil C, Schmidt E, Golub TR, Iliopoulos O
The connectivity map links iron regulatory protein-1-mediated inhibition of hypoxia-inducible factor-2a translation to the anti-inflammatory 15-deoxy-delta12,14-prostaglandin J2. Cancer Res. 2010 Apr 15; 70(8):3071-9.
The connectivity map links iron regulatory protein-1-mediated inhibition of hypoxia-inducible factor-2a translation to the anti-inflammatory 15-deoxy-delta12,14-prostaglandin J2.
Iliopoulos O, Baroody FM, Naclerio RM, Bochner BS, Kagey-Sobotka A, Lichtenstein LM
Journal of immunology (Baltimore, Md. : 1950)
Histamine-containing cells obtained from the nose hours after antigen challenge have functional and phenotypic characteristics of basophils. J Immunol. 1992 Apr 01; 148(7):2223-8.
Histamine-containing cells obtained from the nose hours after antigen challenge have functional and phenotypic characteristics of basophils.
Corless CL, Kibel AS, Iliopoulos O, Kaelin WG
Immunostaining of the von Hippel-Lindau gene product in normal and neoplastic human tissues. Hum Pathol. 1997 Apr; 28(4):459-64.
Immunostaining of the von Hippel-Lindau gene product in normal and neoplastic human tissues.
Neumann HP, Hoegerle S, Manz T, Brenner K, Iliopoulos O
How many pathways to pheochromocytoma? Semin Nephrol. 2002 Mar; 22(2):89-99.
Lieubeau-Teillet B, Rak J, Jothy S, Iliopoulos O, Kaelin W, Kerbel RS
von Hippel-Lindau gene-mediated growth suppression and induction of differentiation in renal cell carcinoma cells grown as multicellular tumor spheroids. Cancer Res. 1998 Nov 01; 58(21):4957-62.
von Hippel-Lindau gene-mediated growth suppression and induction of differentiation in renal cell carcinoma cells grown as multicellular tumor spheroids.